CLAIMS

1. Use of a checkpoint inhibitor (CPI) in the manufacture of a medicament for the therapeutic treatment of metastases of colorectal cancer to a liver in a human subject in a package together with instructions for its use by locoregional delivery with a hepatic arterial infusion (HAI) device in the treatment of metastases of colorectal cancer to a liver.

2. The use of claim 1, wherein the CPI comprises a Programmed Death 1 receptor (PD-1) antagonist.

3. The use of claim 2, wherein the PD-1 antagonist is at least one of nivolumab, pembrolizumab, and cemiplimab.

4. The use of claim 1, wherein the CPI comprises a Programmed Cell Death 1 Ligand 1 (PD-L1) antagonist.

5. The use of claim 4, wherein the PD-L1 antagonist is at least one of atezolizumab, avelumab, and durvalumab.

6. The use of claim 1, wherein the HAI device is a catheter device.

7. The use of claim 6, wherein the catheter device responds dynamically to local pressure and/or flow changes.

8. The use of claim 7, wherein the catheter device is a pressure-enabled drug delivery device.

9. The use of claim 1, wherein the CPI is at a dose selected from the range of 0.01-10 mg/kg.

10. Use of a checkpoint inhibitor (CPI) in the manufacture of a medicament for the treatment of in a human subject in a package together with instructions for its use by

locoregional delivery with a pancreatic retrograde venous infusion (PRVI) device in the treatment of pancreatic cancer.

11. The use of claim 10, wherein the CPI comprises a Programmed Death 1 receptor (PD-1) antagonist.

12. The use of claim 11, wherein the PD-1 antagonist is at least one of nivolumab, pembrolizumab, and cemiplimab.

13. The use of claim 10, wherein the CPI comprises a Programmed Cell Death 1 Ligand 1 (PD-L1) antagonist.

14. The use of claim 13, wherein the PD-L1 antagonist is at least one of atezolizumab, avelumab, and durvalumab.

15. The use of claim 10, wherein the PRVI device is a catheter device.

16. The use of claim 15, wherein the catheter device is a pressure-enabled drug delivery device.

17. The use of claim 10, wherein the CPI is at a dose selected from the range of 0.01-10 mg/kg.